Increasingly sensitive techniques are available for the detection and quantification of
MRD in multiple myeloma. Each technique offers advantages and inherent limitations that
might differentially affect their use and interpretation of the findings.72
ASO, allele-specific oligonucleotide; CT, computed tomography; MFC,
multiparameter flow cytometry; MRD, minimal residual disease; NGS, next-generation
sequencing; PCR, polymerase chain reaction; PET, positron emission tomography.
A publication from the U.S. Food & Drug Administration (FDA)
discussing regulatory perspectives on MRD testing in multiple myeloma concluded that
MRD assessment in multiple myeloma has the potential to become a surrogate clinical
endpoint that could be used to support regulatory purposes for drug review.
Standardization of MRD testing and consensus within the multiple myeloma community
as to the role of MRD will be integral steps toward this end.73
Multiple myeloma is an evolving disease state, and Amgen plans several substantive updates to the content of this site in the coming months. Please subscribe to be notified as these updates become available. Your email will not be used for any other purpose, and you can unsubscribe at any time.
Please send me a notification when myelomarevealed.com content is updated.